title: [Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts].
abstract: OBJECTIVE
  The aim of this study was to assess the prevalence of infection by HCV, HBV, HDV and HIV and their biological and histopathological patterns in 104 intravenous drug users.
  
  
  RESULTS
  Seventy-five patients (72%) had anti-HCV antibodies. Transmission was rapid because 33% of those who had been drug users for 6 months or less had anti-HCV antibodies. The contamination rate was very high because 90% of those who had been drug users for 2 years or less had anti-HCV antibodies. Thirty-four (33%) had an HBV marker, and 6 were HBs Ag carriers. None of the patients had anti-HDV antibodies. Only one patient had anti-HIV antibodies. Twenty-five anti-HCV antibody positive drug users underwent liver biopsy. Seven (28%) had normal ALAT levels and 18 (72%) had permanently or intermittently elevated ALAT levels. The mean histological activity on the Knodell index was 4.1 (range: 1-8).
  
  
  CONCLUSIONS
  This study indicates that contamination by HCV is almost inevitable after 2 years of intravenous drug use. The low prevalence of HBV, HDV, and HIV infection might be explained by a low endemic state of these viruses in our area.
authors.affiliation: Service de Pathologie Digestive, CH Saint-Philibert, Lomme.
authors.forename: D
authors.initials: D
authors.lastname: Lucidarme
authors.forename: P
authors.initials: P
authors.lastname: Foutrein
authors.forename: C
authors.initials: C
authors.lastname: Creusy
authors.forename: G
authors.initials: G
authors.lastname: Forzy
authors.forename: M C
authors.initials: MC
authors.lastname: Foutrein-Comes
authors.forename: A
authors.initials: A
authors.lastname: Muyssen
authors.forename: D
authors.initials: D
authors.lastname: Bailly
authors.forename: P J
authors.initials: PJ
authors.lastname: Parquet
authors.forename: B
authors.initials: B
authors.lastname: Filoche
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000032:analysis*; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology* / Q000209:etiology; D006526:Hepatitis C / Q000453:epidemiology* / Q000209:etiology; D003699:Hepatitis D / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D015995:Prevalence; D011446:Prospective Studies; D019966:Substance-Related Disorders / Q000150:complications*
chemical_list: D015415:Biomarkers